What is the process called for monitoring safety after a drug is on the market?

• A. Post-Marketing Surveillance
• B. Phase 3 clinical trials
• C. NDA
• D. IND

Answer: (A)

Monitoring safety after a drug is on the market is pharmacovigilance, often called post-marketing surveillance. The idea is that once a drug is used by a broad and diverse population, rare or long-term adverse effects may appear that weren’t seen in preapproval trials. By collecting and analyzing reports of adverse events, regulators and manufacturers can detect safety signals, quantify risk, and determine whether labeling should be updated, warnings added, usage restricted, or the product withdrawn. This ongoing process ensures the risk–benefit balance remains acceptable in real-world use and is sometimes supported by Phase 4 studies, spontaneous reporting systems, and observational research. In contrast, Phase 3 trials occur before approval to assess efficacy and safety in a controlled, premarket setting; an NDA is the application to gain approval; and an IND is permission to start clinical trials.